Bénédicte Dubois
A5100754074- Multiple Sclerosis Research Studies
- T-cell and B-cell Immunology
- Systemic Lupus Erythematosus Research
- Immunotherapy and Immune Responses
- Protease and Inhibitor Mechanisms
- Cytokine Signaling Pathways and Interactions
- Amyotrophic Lateral Sclerosis Research
- Polyomavirus and related diseases
- Systemic Sclerosis and Related Diseases
- Neurogenetic and Muscular Disorders Research
- Immune Cell Function and Interaction
- RNA regulation and disease
- Viral Infections and Immunology Research
- Rheumatoid Arthritis Research and Therapies
- Peripheral Neuropathies and Disorders
- Monoclonal and Polyclonal Antibodies Research
- Immune Response and Inflammation
- Mycobacterium research and diagnosis
- Genetic Associations and Epidemiology
- Immunodeficiency and Autoimmune Disorders
- RNA Research and Splicing
- T-cell and Retrovirus Studies
- Neuroinflammation and Neurodegeneration Mechanisms
- vaccines and immunoinformatics approaches
- Health, Medicine and Society
KU Leuven
2015-2024
Allen Institute for Brain Science
2019-2024
VIB-KU Leuven Center for Brain & Disease Research
2018-2022
Sorbonne Université
2020
University of Pennsylvania
2020
NeuroRx Research (Canada)
2018
Universitair Ziekenhuis Leuven
2005-2018
Vrije Universiteit Amsterdam
2018
Center for Human Genetics
2011
University of Cambridge
2007-2009
We analyzed genetic data of 47,429 multiple sclerosis (MS) and 68,374 control subjects established a reference map the architecture MS that includes 200 autosomal susceptibility variants outside major histocompatibility complex (MHC), one chromosome X variant, 32 within extended MHC. used an ensemble methods to prioritize 551 putative genes implicate innate adaptive pathways distributed across cellular components immune system. Using expression profiles from purified human microglia, we...
The prior diagnosis of fatal astrocytoma in a 60-year-old man with Crohn's disease treated natalizumab, monoclonal antibody against alpha4 integrins, was reclassified as JC virus-related progressive multifocal leukoencephalopathy (PML). Analysis frozen serum samples showed that virus DNA had appeared the three months after initiation open-label natalizumab monotherapy and two before appearance symptomatic PML. There staining brain lesion for polyomavirus. This case report, along others,...
<b>Background: </b> There is no consensus method for determining progression of disability in patients with multiple sclerosis (MS) when each patient has had only a single assessment the course disease. <b>Methods: Using data from two large longitudinal databases, authors tested whether cross-sectional assessments are representative disease severity as whole. An algorithm, Multiple Sclerosis Severity Score (MSSS), which relates scores on Expanded Disability Status Scale (EDSS) to...
Matrix metalloproteinases (MMPs) form a family of enzymes with major actions in the remodeling extracellular matrix (ECM) components. Gelatinase B (MMP-9) is most complex member terms domain structure and regulation its activity. activity under strict control at various levels: transcription gene by cytokines cellular interactions; activation pro-enzyme cascade comprising serine proteases other MMPs; specific tissue inhibitors MMPs (TIMPs) or unspecific inhibitors, such as...
We used data from 13 adult neurology departments affiliated with the European Database for Multiple Sclerosis (EDMUS) network to identify a cohort of 394 patients who had multiple sclerosis an onset at 16 years age or younger and comparison group 1775 after age. determined initial clinical features, dates disease onset, occurrence outcomes, including relapse, conversion secondary progression, irreversible disability as measured by scores 4 (limited walking ability but walk more than 500 m...
Regulated expression of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) plays a role in various physiological processes. To determine vivo how unbalanced these factors can promote or affect the course pathologies, we knocked out mouse gelatinase B gene by replacing catalytic zinc-binding domains with an antisense-oriented neomycin resistance gene. Adult B–deficient mice wild-type controls could be induced to develop experimental autoimmune encephalomyelitis (EAE) similar scores...
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system associated with demyelination and axonal loss. A whole genome association scan suggested that allelic variants in CD58 gene region, encoding costimulatory molecule LFA-3, are risk developing MS. We now report additional genetic evidence, as well resequencing fine mapping locus patients MS control subjects. These efforts identify a variant provides further evidence (P = 1.1 x 10(-6), OR 0.82) single protective...
Abstract Accumulating evidence indicates an immunosuppressive role for CD4 + CD25 regulatory T cells (Tregs) in autoimmune diseases. Although impaired Treg function patients with relapsing‐remitting multiple sclerosis (RR‐MS) has been reported recently, no information is available so far about the progressive stage of disease. In present study, phenotypic and functional characteristics isolated from peripheral blood RR‐MS secondary (SP‐MS) were investigated. No significant quantitative or...
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of motor neurons that results in progressive muscle weakness and limits survival to 2-5 years after disease onset. Intermediate CAG repeat expansions ataxin 2 (ATXN2), the causative gene spinocerebellar ataxia type (SCA2), have been implicated sporadic ALS. We studied ATXN2 large cohort patients with familial ALS.We determined size 1,948 ALS cases 2,002 controls from Belgium Netherlands.In controls, maximal was 31. In ALS,...
Multiple sclerosis is a complex neurological disease, with ∼20% of risk heritability attributable to common genetic variants, including >230 identified by genome-wide association studies. strands evidence suggest that much the remaining also due additive effects variants rather than epistasis between these or mutations exclusive individual families. Here, we show in 68,379 cases and controls up 5% this explained low-frequency variation gene coding sequence. We identify four novel genes...
Abstract IL-17-producing helper T (Th17) cells are critical for host defense against extracellular pathogens but also drive numerous autoimmune diseases. Th17 that differ in their inflammatory potential have been described including IL-10-producing weak inducers of inflammation and highly inflammatory, IL-23-driven, GM-CSF/IFNγ-producing cells. However, distinct developmental requirements, functions trafficking mechanisms vivo remain poorly understood. Here we identify a temporally regulated...
To assess outcomes for patients treated with interferon beta-1b immediately after clinically isolated syndrome (CIS) or a short delay.Participants in BENEFIT (Betaferon/Betaseron Newly Emerging MS Initial Treatment) were randomly assigned to receive (early treatment) placebo (delayed treatment). After conversion definite multiple sclerosis (CDMS) 2 years, on could switch another treatment. Eleven years randomization, reassessed.Two hundred seventy-eight (59.4%) of the original 468 (71.3%...
Abstract: We assembled and analyzed genetic data of 47,351 multiple sclerosis (MS) subjects 68,284 control establish a reference map the architecture MS that includes 200 autosomal susceptibility variants outside major histocompatibility complex (MHC), one chromosome X variant, 32 independent associations within extended MHC. used an ensemble methods to prioritize up 551 potentially associated genes, implicate innate adaptive pathways distributed across cellular components immune system....
<h3>Abstract</h3> <h3>Background:</h3> Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with relapsing-remitting multiple sclerosis (MS), is a disease-modifying therapy potential immunomodulatory and neuroprotective effects. In clinical trials, DMF was associated reduced white blood cell absolute lymphocyte counts. Current US prescribing information recommends obtaining complete count, including count (ALC), before initiating during treatment....